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Forty patients with arthritis (26 rheumatoid and 14 osteoarthrosis) entered a five-week double-blind 
crossover trial of diclofenac and ibuprofen. Four patients failed to complete the 10-week trial. There 
was no statistically significant difference in parameters of disease activity for the rheumatoid arthritis 
patients, but patients with osteoarthrosis fared significantly better on diclofenac. There was a low 
incidence of side effects on both regimens. 
 
Diclofenac Sodium (Voltaren) is a non-steroidal non-pyrazole compound with anti-
inflammatory, antipyretic and analgesic activity in laboratory animals.1 It has been 
shown to be well tolerated and effective in short-term therapy of degenerative joint 
disease2 and rheumatoid arthritis. To assess the place of diclofenac in clinical practice, 
we studied the effectiveness of this drug against ibuprofen in patients with rheumatoid 
arthritis and osteoarthrosis. 
 
METHODS 
A five-week double-blind crossover design was used, each patient receiving either 
Voltaren plus ibuprofen placebo or Voltaren placebo plus Ibuprofen, with treatments 
commencing in a random fashion. Diclofenac was presented as 25-mg enteric-coated 
tablets and ibuprofen was presented as 400-mg film-coated tablets. Treatment was 
commenced on a dose of 75 mg of diclofenac (one three times a day) or 1200 mg of 
ibuprofen : (one three times a day) and the dose was adjusted upwards if necessary at 
the end of weeks one and two. Patients then continued their dose for the three-week 
test period before changing over to the other medication.  
 
The majority of patients in each group took 100 mg of diclofenac and 1600 mg of 
ibuprofen for the three-week test period. Patients with significant renal or liver 
impairment were excluded from the study, but patients on stable doses of 
prednisolone, gold and D-penicillamine were included. There were four patients on 
maintenance gold therapy, two patients on D-penicillamine therapy and one patient on 
prednisolone (10 mg a day). The following assessments were carried out on the 
patients with rheumatoid arthritis: grip strength according to the method of Lee et 
alii;3 circumference of the proximal interphalangeal joint;4 articular index;5 and the 
duration of morning stiffness. An analogue pain score was taken on a 10-cm line at 
the time of final assessment and, for the last three weeks of each treatment period, 
patients were asked to fill in a daily pain score according to the method of Lee et 
alii.6A visual analogue pain score was also carried out in the patients with 
osteoarthrosis who were also asked to assess the effect of the treatment on pain in 
their most affected joint (this remained the same throughout the trial) on a five point 
scale. A daily pain score was also performed for the final three weeks of each 
treatment period in the osteoarthritic patients. Side effects were assessed at the end of 
each treatment period by asking the patients to comment as to whether they had 
noticed anything abnormal during the test period. 
 
RESULTS 
Rheumatoid Arthritis 
Twenty-six patients entered the trial. Two dropped out: one because of failure to 
control symptoms of pain (on ibuprofen); and one because of indigestion (diclofenac). 
There were 10 males and 16 females with a mean age of 52 years and a mean duration 
of disease activity of nine years. The results of the clinical measurements in the 
rheumatoid arthritic patients are shown in Table 1.  
 
Table 1 : Results of Clinical Assessments 
 
 
 
 Mean values ± standard deviation.  
g mmHg in parentheses.  
NS-not significant. 
 
Osteoarthrosis 
Fourteen patients with osteoarthrosis entered the study. Two dropped out: a 64-year-
old man with a previous history of myocardial infarction died suddenly after an 
episode of central chest pain two weeks after commencing treatment; and one patient 
dropped out because the test medication (ibuprofen) caused an itchy skin rash. The 
results of the clinical assessments in the osteoarthritic patients are shown in Table 1. 
At the end of the trial, patients were asked for a global assessment of the two 
treatment periods. Both the rheumatoid arthritic patients and osteoarthritic patients 
strongly favoured diclofenac over ibuprofen. In the rheumatoid group, 12 of 24 
patients favoured diclofenac and eight found the drugs of equal efficacy. Of the 
osteoarthritic group, eight of 12 patients favoured diclofenac and four patients rated 
the treatments equally. 
 
From Table 1, it can be seen that for patients with rheumatoid arthritis there is no 
significant difference in the clinical parameters measured, though the analogue daily 
pain score during the three-week test period and the duration of morning stiffness are 
less during the diclofenac period. In those patients with osteoarthrosis there is a 
significant difference in the clinical parameters measured in favour of diclofenac. 
 
Side effects occurred in 13 of the 40 patients entering the trial, but required a 
cessation of treatment in only two patients (one on diclofenac and one on ibuprofen). 
 
CONCLUSION 
In this double-blind crossover trial, diclofenac was shown to be equally efficacious to 
ibuprofen for patients with rheumatoid arthritis. In those patients with osteoarthrosis 
diclofenac was shown to be significantly better than ibuprofen in all clinical 
parameters measured. Seven patients on diclofenac and eight patients on ibuprofen 
developed side effects during the trial, though in all but two cases, patients were able 
to continue the trial with disappearance of the side effect. Diclofenac, with its small 
tablet size, tolerability and efficacy will certainly be a useful additive to the non-
steroidal anti-inflammatory drug range for the treatment of osteoarthrosis and 
rheumatoid arthritis. Further trials against the new propionic acid derivatives are 
awaited to assess its proper place in the antirheumatic armamentarium. 
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